All In Biotech

Drug Trial Radar · NCT06379217

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

A Phase I, Open-label, Multi-center Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

31

Actual

Start

Jul 29, 2024

Primary completion

Oct 16, 2026

Study completion Oct 16, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the change in the expression of treatment targets on the surface of tumor cells (Prostate Specific Membrane Antigen (PSMA), Somatostatin Receptor 2 (SSTR2), and Gastrin Releasing Peptide Receptor (GRPR) between the baseline and following targeted radioligand therapy (RLT). The study used radioligand imaging (RLI) to determine predominantly expressed target on the surface of tumor cells. Based on predominant expression of target, corresponding RLT targeting PSMA, SSTR2, or GRPR RLT was given for up to 6 cycles every 6 weeks as intravenous (i.v.) injection in participants with metastatic neuroendocrine prostate cancer (mNEPC).

Conditions

  • Metastatic Neuroendocrine Prostate Cancer

Interventions

  • [68Ga]Ga-PSMA-11Drug

    \[68Ga\]Ga-PSMA-11 was administered as a single intravenous dose of approximately 150 MBq (4 mCi) to be administered during baseline imaging and at any time ≥ 6 weeks after first RLT dose. Sites could consider doing PET/CT imaging with RLT corresponding RLI as the first of three PET/CT scans. Administered dose was not to be lower than 111 MBq (3 mCi) or higher than 259 MBq (7 mCi)

  • [68Ga]GA-DOTA-TATEDrug

    \[68Ga\]Ga-DOTA-TATE was administered as a single intravenous dose to be administered during baseline imaging and at any time ≥ 6 weeks after first RLT dose. Sites could consider doing PET/CT imaging with RLT corresponding RLI as the first of three PET/CT scans. within a range of 100-200MBq (2.7-5.4 mCi)

  • [68Ga]Ga-NeoBDrug

    \[68Ga\]Ga-NeoB was administered as a single intravenous dose to be administered during baseline imaging and at any time ≥ 6 weeks after first RLT dose. Sites could consider doing PET/CT imaging with RLT corresponding RLI as the first of three PET/CT scans. within a range of 150-250 MBq (4.1-6.8 mCi).

  • [177Lu]Lu-PSMA-617Drug

    \[177Lu\]Lu-PSMA-617 was administered as an intravenous infusion at a dose of 7.4 GBq (200mCi) (+/- 10%), every 6 weeks for 6 cycles.

  • [177Lu]Lu-DOTA-TATEDrug

    \[177Lu\]Lu-DOTA-TATE was administered as an intravenous infusion at a dose of 7.4 GBq (200mCi) (+/- 10%) every 6 weeks for 6 cycles.

  • [177Lu]Lu-NeoBDrug

    \[177Lu\]Lu-NeoB was administered as an intravenous infusion at a dose of 9.25 GBq (250mCi) every 6 weeks for 6 cycles

  • L-Lysine HCl-L-Arginine HCl, 2.5 %,Drug

    sterile solution for infusion Lysine HCl-Arginine HCl, 2.5 % (1L)

  • Gonadotropin-releasing hormone (GnRH) analoguesDrug

    Anatomical Therapeutic Chemical \[ATC\] code L02AE

  • GnRH antagonistsDrug

    abarelix, degarelix, or relugolix

  • Antiemetics & antinauseantsDrug

    ATC code A04A

  • MetoclopramideDrug

    ATC code A03FA01

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number/extent of lesions with at least a moderate uptake of any of the Radioligand Imaging (RLI)Time frame: Baseline (baseline imaging is performed during the 42 day screening period)
  2. Percentage changes in quantitative PET parameters.Time frame: Post-Baseline (from date of baseline imaging scans to post-baseline scans, at least 6 weeks after receiving the first cycle of radioligand treatment)

Locations

9 sites in 5 countries. Site status is shown where the registry gives one.

  • Nebraska Cancer Specialists

    Omaha, Nebraska

  • Memorial Sloan Kettering Cancer Ctr

    New York, New York

  • Novartis Investigative Site

    Nantes, France

  • Novartis Investigative Site

    München, Germany

  • Novartis Investigative Site

    Rostock, Germany

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    L'Hospitalet de Llobregat, Barcelona, Spain

  • Novartis Investigative Site

    London, United Kingdom

  • Novartis Investigative Site

    Sutton, Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.